MiTF renal cell carcinoma can masquerade as other subtypes and may not respond as well to front-line therapies.
Cancer: Cancer Types
Study findings support the recent FDA approval of the immunotherapy agent for patients whose cancers have high number of mutations.
Clinical guidelines have encouraged the integration of palliative care, yet medicine lags far behind its goals for ovarian cancer, especially for people of color.
Scientists have long sought to target the interaction between the proteins p53 and Mdm2 in tumor cells, but their interaction in immune cells may be just as important.
Breast cancer stem cells from patients with different racial and ethnic backgrounds showed important differences in activation of immune response-related genes in mouse models.
Studies suggest the gut microbiome can influence immunotherapy side effects. Butyrate emerges as an intriguing candidate against inflammation in the colon.